{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T10:43:54Z","timestamp":1774003434353,"version":"3.50.1"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1097\/cad.0b013e32832b2ea0","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T08:26:00Z","timestamp":1242894360000},"page":"616-624","source":"Crossref","is-referenced-by-count":96,"title":["Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer"],"prefix":"10.1097","volume":"20","author":[{"given":"Giulia","family":"Bianchi","sequence":"first","affiliation":[]},{"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[]},{"given":"Claudio","family":"Zamagni","sequence":"additional","affiliation":[]},{"given":"Stefania","family":"Salvagni","sequence":"additional","affiliation":[]},{"given":"Guenter","family":"Raab","sequence":"additional","affiliation":[]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[]},{"given":"Nicole","family":"Laferriere","sequence":"additional","affiliation":[]},{"given":"Carol","family":"Pe\u00f1a","sequence":"additional","affiliation":[]},{"given":"Chetan","family":"Lathia","sequence":"additional","affiliation":[]},{"given":"Loredana","family":"Bergamini","sequence":"additional","affiliation":[]},{"given":"Luca","family":"Gianni","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-11-20210203","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cncr.11859","article-title":"Is breast cancer survival improving?","volume":"100","author":"Giordano","year":"2004","journal-title":"Cancer"},{"key":"R2-11-20210203","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"R3-11-20210203","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"R4-11-20210203","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J Clin Oncol"},{"key":"R5-11-20210203","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.2007.14.8288","article-title":"Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group","volume":"26","author":"McDermott","year":"2008","journal-title":"J Clin Oncol"},{"key":"R6-11-20210203","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1172\/JCI119309","article-title":"Hyperexpression of mitogen-activated protein kinase in human breast cancer","volume":"99","author":"Sivaraman","year":"1997","journal-title":"J Clin Invest"},{"key":"R7-11-20210203","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R","article-title":"Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients","volume":"89","author":"Mueller","year":"2000","journal-title":"Int J Cancer"},{"key":"R8-11-20210203","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1158\/0008-5472.CAN-05-3243","article-title":"Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance","volume":"66","author":"Cui","year":"2006","journal-title":"Cancer Res"},{"key":"R9-11-20210203","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/ijc.21865","article-title":"The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma","volume":"119","author":"Wu","year":"2006","journal-title":"Int J Cancer"},{"key":"R10-11-20210203","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ejca.2008.01.005","article-title":"The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab","volume":"44","author":"Marty","year":"2008","journal-title":"Eur J Cancer"},{"key":"R11-11-20210203","first-page":"S6","article-title":"A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100) [abstract]","volume":"94","author":"Miller","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"R13-11-20210203","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"R14-11-20210203","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaad.2008.06.034","article-title":"Dermatologic symptoms associated with the multikinase inhibitor sorafenib","volume":"60","author":"Robert","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R15-11-20210203","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/cncr.22255","article-title":"Serum epidermal growth factor receptor\/HER-2 predicts poor survival in patients with metastatic breast cancer","volume":"107","author":"Souder","year":"2006","journal-title":"Cancer"},{"key":"R16-11-20210203","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1586\/14737159.7.3.309","article-title":"Circulating oncoproteins HER2\/neu, EGFR and CAIX (MN) as novel cancer biomarkers","volume":"7","author":"Carney","year":"2007","journal-title":"Expert Rev Mol Diagn"},{"key":"R17-11-20210203","first-page":"1479","article-title":"Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer","volume":"26","author":"Muller","year":"2006","journal-title":"Anticancer Res"},{"key":"R18-11-20210203","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.seminoncol.2003.08.013","article-title":"A phase I\/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer","volume":"30","author":"Cobleigh","year":"2003","journal-title":"Semin Oncol"},{"key":"R19-11-20210203","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.2007.14.5375","article-title":"Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"26","author":"Burstein","year":"2008","journal-title":"J Clin Oncol"},{"key":"R20-11-20210203","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R21-11-20210203","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"key":"R22-11-20210203","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J Clin Oncol"},{"key":"R23-11-20210203","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF00666177","article-title":"The type I growth factor receptors in human breast cancer","volume":"29","author":"Rajkumar","year":"1994","journal-title":"Breast Cancer Res Treat"},{"key":"R24-11-20210203","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit Rev Oncol Hematol"},{"key":"R25-11-20210203","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1159\/000227606","article-title":"Tissue expression and serum levels of HER-2\/neu in patients with breast cancer","volume":"54","author":"Krainer","year":"1997","journal-title":"Oncology"},{"key":"R26-11-20210203","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/annonc\/mdi059","article-title":"Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate","volume":"16","author":"Fornier","year":"2005","journal-title":"Ann Oncol"},{"key":"R27-11-20210203","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0002-9610(05)80897-9","article-title":"Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients","volume":"164","author":"Osaki","year":"1992","journal-title":"Am J Surg"},{"key":"R28-11-20210203","first-page":"1331","article-title":"The course of serum HER-2\/neu levels as an independent prognostic factor for survival in metastatic breast cancer","volume":"11","author":"Schippinger","year":"2004","journal-title":"Oncol Rep"},{"key":"R29-11-20210203","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/cncr.21202","article-title":"Serum HER-2\/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy","volume":"104","author":"Lipton","year":"2005","journal-title":"Cancer"},{"key":"R30-11-20210203","first-page":"2909","article-title":"Biomarkers associated with clinical outcomes in TARGETs, a phase III single-agent, placebo-controlled study of sorafenib in advanced renal cell carcinoma [abstract]","volume":"47","author":"Elting","year":"2006","journal-title":"Proc Amer Assoc Cancer Res"},{"issue":"Suppl","key":"R31-11-20210203","first-page":"5023","article-title":"Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract]","volume":"25","author":"Bukowski","year":"2007","journal-title":"J Clin Oncol ASCO Meeting Proceedings Part I"},{"key":"R32-11-20210203","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"R33-11-20210203","first-page":"578","article-title":"Effects of treatment with sunitinib maleate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer [abstract]","volume":"24","author":"Deprimo","year":"2006","journal-title":"J Clin Oncol ASCO Meeting Proc Part I"},{"key":"R34-11-20210203","doi-asserted-by":"crossref","first-page":"8136","DOI":"10.1200\/JCO.2005.02.5635","article-title":"Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients","volume":"23","author":"Willett","year":"2005","journal-title":"J Clin Oncol"},{"key":"R35-11-20210203","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdi118","article-title":"Soluble markers for the assessment of biological activity with PTK787\/ZK 222584 (PTK\/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials","volume":"16","author":"Drevs","year":"2005","journal-title":"Ann Oncol"},{"key":"R36-11-20210203","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-5-32","article-title":"Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins","volume":"5","author":"Deprimo","year":"2007","journal-title":"J Transl Med"},{"key":"R37-11-20210203","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1023\/A:1008377921886","article-title":"Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?","volume":"10","author":"Wynendaele","year":"1999","journal-title":"Ann Oncol"},{"key":"R38-11-20210203","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1634\/theoncologist.2007-0233","article-title":"Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors","volume":"13","author":"Dal Lago","year":"2008","journal-title":"Oncologist"},{"key":"R39-11-20210203","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00280-007-0639-9","article-title":"Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials","volume":"61","author":"Takimoto","year":"2008","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0b013e32832b2ea0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:13:40Z","timestamp":1620947620000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-200908000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32832b2ea0","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}